GLP1R and type 2 diabetes mellitus: For instance, 700 obese HFpEF patients with or without T2DM will be included in the ongoing SUMMIT research to assess the effectiveness of the GLP-1/GLP-1 R dual agonist tirzepatide (Gallo and Volpe, 2024).